Amol Akhade: ESMO Gynaecology 2025 Highlights – Redefining Maintenance Strategies in Ovarian Cancer
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, posted on LinkedIn:
“ESMO Gynaecology 2025 Highlights: Redefining Maintenance Strategies in Ovarian Cancer. Vienna, June 19–21
A new era is dawning in the management of high-grade serous ovarian cancer (HGSC), especially for the HRD+ population (~50% of HGSC). Key takeaways from this year’s presentations: PARP Inhibitors Still Central
PFS benefit in HRD+ (BRCA-wt) seen across:
• PAOLA-1 (Olaparib+Bev): 28.1 vs 16.6 mo (HR 0.43)
• PRIMA (Niraparib): 19.6 vs 8.2 mo (HR 0.50)
• ATHENA-MONO (Rucaparib): 20.3 vs 9.2 mo (HR 0.58)
OS benefit confirmed in HRD+ (5y OS: 65.5% vs 48.4%). Concern: platinum resistance is higher post-PARPi progression. Optimal duration of PARPi? Still unclear (2–3 years?)
Targeted Maintenance Beyond PARPi: What’s Coming Next? ADCs (Antibody-Drug Conjugates) making their way into 1st-line maintenance:
- BEV +/- T-DXd for HER2+
- BEV +/- FRα-ADC
- BEV +/- TROP2-ADC
Questions remain on optimal duration and biomarker selection. Immunotherapy + Vaccines. Vaccine + ICI (e.g., TEDOPI) under evaluation in PSOC.
BiTEs: modest response rates but offer disease control. Novel combinations in trials aiming for chemo-free maintenance
CCNE1-high Disease: A Tough Subset. WEE1 (azenosertib) and CDK2 (INCB123667) inhibitors showing ORR ~30–35%. Potential for early-line use with BEV
Toxicities (hematologic, GI) need careful consideration. Biomarker-driven therapy, personalized combinations, and earlier maintenance interventions will likely shape the future of ovarian cancer care.”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023